Methods of treatment for solid tumors

Abstract

The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula I, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such compound admixed with at least one pharmaceutically acceptable excipient.

1 . A method of treating a solid tumor in a subject comprising administering to said subject an optically active compound of formula I 
       
         
           
           
               
               
           
         
       
       a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising an optically active compound of Formula I or a pharmaceutically acceptable salt thereof;
 wherein the amount of the compound of Formula I or its salt is an amount effective to treat the solid tumor. 
 
     
     
         2 . The method of  claim 1 , wherein the solid tumor is selected from the group consisting of pancreatic cancer; bladder cancer; colorectal cancer; breast cancer; prostate cancer; renal cancer; hepatocellular cancer; lung cancer; ovarian cancer; cervical cancer; gastric cancer; esophageal cancer; head and neck cancer; melanoma; neuroendocrine cancers; CNS cancers; brain tumors; bone cancer; and soft tissue sarcoma. 
     
     
         3 . The method of  claim 1 , wherein the solid tumor is selected from non-small cell lung cancer, small-cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer. 
     
     
         4 . The method of  claim 1 , wherein the S-enantiomer predominates over the R enantiomer by a ratio of at least about 9:1. 
     
     
         5 . The method of  claim 1 , wherein the S-enantiomer predominates over the R enantiomer by a ratio of at least about 19:1. 
     
     
         6 . The method of  claim 1 , wherein the compound is administered orally. 
     
     
         7 . The method of  claim 1 , wherein the compound is administered in solid form. 
     
     
         8 . The method of  claim 7 , wherein the solid form comprises the optically active compound of Formula I admixed with at least one pharmaceutically acceptable excipient. 
     
     
         9 . The method of  claim 7 , wherein the solid tumor is ovarian, renal, breast, lung, colon or prostate cancer. 
     
     
         10 . The method of  claim 1  wherein the subject is refractory to chemotherapy treatment, or in relapse after treatment with chemotherapy. 
     
     
         11 . The method of  claim 1  wherein the compound of formula I is administered at a dose of 20-500 mg/day. 
     
     
         12 . The method of  claim 1  wherein the compound of formula I is administered at a dose of 50-250 mg/day. 
     
     
         13 . The method of  claim 1  wherein the compound of formula I is administered at a dose of 50-150 mg twice per day. 
     
     
         14 . The method of  claim 1  wherein a compound of formula I is administered at least twice daily. 
     
     
         15 . The method of  claim 1 , further comprising reducing the level of PI3Kδ activity in said subject. 
     
     
         16 . The method of  claim 1 , wherein the subject is a human subject. 
     
     
         17 . The method of  claim 16 , wherein the concentration of the compound in the blood is between 40-3000 ng/mL over a 12 hour period from the time of administration. 
     
     
         18 . The method of  claim 16 , wherein the concentration of the compound in the blood is between about 100 nM and 2000 nM in the treated subject. 
     
     
         19 . The method of  claim 1 , wherein the agent is administered orally, intravenously or by inhalation. 
     
     
         20 . The method of  claim 1 , further comprising administering in addition to a compound of formula I to said subject, a therapeutically effective amount of at least one therapeutic agent and/or therapeutic procedure selected to treat said solid tumor in said subject. 
     
     
         21 . The method of  claim 20 , wherein said therapeutic agent is selected from the following group consisting of Docetaxel, Mitoxantrone, Prednisone, Estramustine, Anthracyclines, (doxorubicin (Adriamycin), epirubicin (Ellence), and liposomal doxorubicin (Doxil)), Taxanes (docetaxel (Taxotere), paclitaxel (Taxol), and protein-bound paclitaxel (Abraxane)), Cyclophosphamide (Cytoxan), Capecitabine (Xeloda) and 5 fluorouracil (5 FU), Gemcitabine (Gemzar), methotrexate, Vinorelbine (Navelbine), an EGFR inhibitor such as erlotinib, Trastuzumab, Herceptin, Avastin, Platins (cisplatin, carboplatin), Temazolamide, Interferon alpha, and IL-2. 
     
     
         22 . The method of  claim 20 , wherein in said therapeutic agent is selected from the group consisting of an EGFR inhibitor, an mTOR inhibitor, a platin, and a taxane. 
     
     
         23 . The method of  claim 20 , wherein said therapeutic procedure is selected from the group consisting of peripheral blood stem cell transplantation, autologous hematopoietic stem cell transplantation, autologous bone marrow transplantation, antibody therapy, biological therapy, enzyme inhibitor therapy, total body irradiation, infusion of stem cells, bone marrow ablation with stem cell support, in vitro-treated peripheral blood stem cell transplantation, umbilical cord blood transplantation, immunoenzyme technique, immunohistochemistry staining method, pharmacological study, low-LET cobalt-60 gamma ray therapy, bleomycin, conventional surgery, radiation therapy, high-dose chemotherapy and nonmyeloablative allogeneic hematopoietic stem cell transplantation. 
     
     
         24 . The method of  claim 1  further comprising obtaining a biological sample from said subject; and analyzing said biological sample with an analytical procedure selected from the group consisting of blood chemistry analysis, chromosomal translocation analysis, needle biopsy, fluorescence in situ hybridization, laboratory biomarker analysis, immunohistochemistry staining method, flow cytometry or a combination thereof. 
     
     
         25 . The method of  claim 24 , wherein the compound is administered twice daily for about 28 days, and is then discontinued for at least 7 days.